An enzyme immunosorbent assay of neopterin and biopterin on a polystyrene microtiter plate has been developed. A conjugate of neopterin or biopterin to bovine serum albumin was used to raise a specific antiserum against neopterin or biopterin in rabbits. An incubation mixture of the antiserum and samples prepared from human serum underwent another antigen-antibody reaction with the hapten fixed on the microtiter plate. The amount of antibody bound to the fixed hapten, which is inverse to the amount of hapten in the sample, was determined by using anti-rabbit IgG-horseradish peroxidase conjugate in a usual manner by measuring absorbance at 490 nm after reaction with o-phenylenediamine and hydrogen peroxide. The minimal detectable amounts of neopterin and biopterin were -0.1 pmol. The specificity of the assay was so high that the assay system for neopterin completely distinguished it from biopterin, as judged from the cross-reaction of 0.002%, and vice versa.
The amounts of neopterin and biopterin in human serum determined by the present method agreed well with those determined by high-performance liquid chromatography. We used the present method to determine the concentrations of neopterin in serum from healthy control subjects and patients with cancers and systemic lupus erythematosus; the results were consistent with literature data. the method is simple and overcomes the above-mentioned problems. A preliininary part of this study appeared elsewhere (9).
MaterIals and Methods

Materials
Specific antisera against neopterin and biopterin. The specific antisera against neopterin and biopterin were prepared in rabbits by using neopterinylcaproylor biopterinylcaproyl-bovine serum albumin conjugate as the antigen, as previously reported 
Results
Sensitivity
and specificity. The measurable amounts of neopterin and biopterin in the present immunoassay ranged from -0.1 pmol (30 pg) to 100 pmol (3 ng) per well for each, as shown in the standard curves ( Figure  2 ). The sensitivity (detection limit) of the present assay was almost equivalent to those of previously reported radioimmunoassays (10, 11). Addition of normal sheep serum to the dilution media of the antisera and treatment with kaolin effectively suppressed the nonspecific binding of the antibodies to the plate. In a typical experiment, the B0 value, which corresponds to the amount of antiserum bound to the fixed hapten on the (Table 2) . We used the present method to determine the concentrations of neopterin in serum from healthy control subjects and patients with cancers and systemic lupus 
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- (1, 15) . Because the assessments of native neopterin and total neopterin (neopterin and reduced derivatives) are of almost equal diagnostic potential (22, 23), only the native neopterin was measured in the present study, to make the procedure less laborious. As shown in Figure  5 , the neopterin concentrations in serum from myeloma, prostatic cancer, hepatoma, lymphoma, and lung cancer patients were four-to fivefold higher than the control value (P <0.005). Patients with other cancers such as ovarian cancer, acute myelocytic leukemia, and bladder cancer all exhibited lower values: only 1.5-to 2.5-fold that of the control value; nonetheless, the P-values were <0.01. Patients with systemic lupus erythematosus also exhibited significantly high (P <0.005) neopterin concentrations in serum, as reported elsewhere (20) .
In a separate experiment, we used the present method to measure the total neopterin (native neopterin plus its reduced derivatives) in serum of healthy control subjects and patients with various types of cancer (data not shown). In contrast to the observations previously reported and also to our present observation, we saw no significant correlation between the serum concentrations of neopterin and these forms of cancer (control value: 14.5 nmolIL). Perhaps the patients with the malignant diseases we studied have low concentrations of reduced derivatives of neopterin in serum.
We conclude that the present method is very useful for determining serum neopterin concentrations, which is difficult by other methods because of the low concentrations involved. However, the procedure for sample preparation is still cumbersome and needs to be improved.
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